The costs of infusion versus bolus administration of chemotherapy has been a point of controversy as has been the method of quantitating the cost.
The present study analyzes the reimbursement for chemotherapy administration by infusion compared with bolus delivery based on reimbursement and relates this to cost based on projected charges and actual charges in a private practice setting.
Actual reimbursement records were retrieved for selected patients receiving infusion or bolus administration of specific chemotherapy regimens for three tumors : colon carcinoma, breast carcinoma, and lymphoma.
All services were included except for radiology and hospitalization.
Medicare reimbursement represented 90% of the treatment cycles analyzed.
Actual reimbursement per month for each infusion regimen was as follows :
colon carcinoma, $528 (5-fluorouracil [5-FU]) ;
breast carcinoma, $621 (doxorubicin and cyclophosphamide [AC]) and $685 (cyclophosphamide, methotrexate, and fluorouracil [CMF]) ;
and lymphoma, $603 (cyclophosphamide, doxorubicin, vincristine, and prednisone ICHOPI).
Actual reimbursement per month for a bolus regimen was colon carcinoma, $393 (5-FU+leucovorin) ; breast carcinoma, $991 (AC) or $453 (CMF) ; and lymphoma, $749 (CHOP).
Actual reimbursement represents 21-36% of actual charges.
Projected charges based on the model system are generally less than the actual charges.
Mots-clés Pascal : Tumeur maligne, Côlon, Glande mammaire, Lymphome non hodgkinien, Homme, Chimiothérapie, Traitement, Voie intraveineuse, Perfusion, Injection bolus, Analyse coût, Anticancéreux, Appareil digestif pathologie, Intestin pathologie, Côlon pathologie, Glande mammaire pathologie, Hémopathie maligne, Lymphoprolifératif syndrome, Economie santé
Mots-clés Pascal anglais : Malignant tumor, Colon, Mammary gland, Non Hodgkin lymphoma, Human, Chemotherapy, Treatment, Intravenous administration, Perfusion, Bolus injection, Cost analysis, Antineoplastic agent, Digestive diseases, Intestinal disease, Colonic disease, Mammary gland diseases, Malignant hemopathy, Lymphoproliferative syndrome, Health economy
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 96-0329347
Code Inist : 002B02R01. Création : 10/04/1997.